| model_name,score,EASI-50,Time,EASI percent reduction,EASI-50 response,VSI [66],SITE [57],MMSI [68],OmniSpatial [23],MindCube ∗ [69],STARE [32],CoreCognition [33],SpatialViz [55],EASI 75 achievement rate,EASI score reduction (%),percentage MIC,efficiency,specificity,median EASI,source_title,source_url,notes | |
| abrocitinib 200 mg QD,86.6,86.6,,,,,,,,,,,,,,,,,,Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis,https://doi.org/10.1111/jdv.17351,Combination therapy RCTs | |
| Upadacitinib,85.6,,Week 12,85.6%,,,,,,,,,,,,,,,,The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan,https://doi.org/10.1111/1346-8138.16549,Median percent reduction in EASI at week 12 with Upadacitinib 15 mg/day plus topical corticosteroids. | |
| upadacitinib 30 mg once daily (QD),83.6,,,,83.6,,,,,,,,,,,,,,,Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis,https://doi.org/10.1111/jdv.17351,Monotherapy RCTs | |
| dupilumab 300 mg Q2W,82.4,82.4,,,,,,,,,,,,,,,,,,Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis,https://doi.org/10.1111/jdv.17351,Combination therapy RCTs | |
| abrocitinib 100 mg QD,79.7,79.7,,,,,,,,,,,,,,,,,,Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis,https://doi.org/10.1111/jdv.17351,Combination therapy RCTs | |
| Human,79.2,,,,,79.2,67.5,97.2,92.63,94.55,96.50,86.98,82.46,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,None | |
| abrocitinib 200 mg QD,74.6,,,,74.6,,,,,,,,,,,,,,,Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis,https://doi.org/10.1111/jdv.17351,Monotherapy RCTs | |
| Upadacitinib,73.6,,Week 4,73.6%,,,,,,,,,,,,,,,,The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan,https://doi.org/10.1111/1346-8138.16549,Median percent reduction in EASI at week 4 with Upadacitinib 15 mg/day plus topical corticosteroids. | |
| upadacitinib 15 mg QD,70.5,,,,70.5,,,,,,,,,,,,,,,Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis,https://doi.org/10.1111/jdv.17351,Monotherapy RCTs | |
| Upadacitinib,67.7,,Week 12,,,,,,,,,,,67.7%,,,,,,The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan,https://doi.org/10.1111/1346-8138.16549,Achievement rate of EASI 75 at week 12 with Upadacitinib 15 mg/day plus topical corticosteroids. | |
| dupilumab 300 mg every 2 weeks (Q2W),63.4,,,,63.4,,,,,,,,,,,,,,,Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis,https://doi.org/10.1111/jdv.17351,Monotherapy RCTs | |
| Qwen3-8B-Instruct [65],57.9,,,,,57.90,45.83,31.10,45.73,29.42,39.76,69.67,17.54 †,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,"† indicates cases where generations were truncated due to overlong chains of thought, yielding no final answer; such instances are counted as incorrect, which depresses the score." | |
| abrocitinib 100 mg QD,56.7,,,,56.7,,,,,,,,,,,,,,,Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis,https://doi.org/10.1111/jdv.17351,Monotherapy RCTs | |
| InternVL3.5-8B [56],56.05,,,,,56.05,43.79,27.30,46.71,42.50,40.18,66.40,23.98,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,None | |
| GPT-5-2025-08-07 [45],55.03,,,,,55.03,61.88,41.80,59.90,56.30,54.59,84.37,51.27,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,None | |
| Gemini-2.5-pro-2025-06 [52],53.57,,,,,53.57,57.06,38.00,55.38,57.60,49.14,76.70,42.71,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,None | |
| Upadacitinib,51.6,,Week 4,,,,,,,,,,,51.6%,,,,,,The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan,https://doi.org/10.1111/1346-8138.16549,Achievement rate of EASI 75 at week 4 with Upadacitinib 15 mg/day plus topical corticosteroids. | |
| high dose hUCB-MSC,50.0,,,,,,,,,,,,,,50.0,,,,,Clinical Trial of Human Umbilical Cord Blood-Derived Stem Cells for the Treatment of Moderate-to-Severe Atopic Dermatitis: Phase I/IIa Studies,https://doi.org/10.1002/stem.2401,Fifty-five percent of patients in high dose hUCB-MSC-treated group showed a 50% reduction in the EASI score. | |
| EASI 50,50.0,,,,,,,,,,,,,,,50.0,,,,What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study*,https://doi.org/10.1111/bjd.19457,Meaningful percentage MIC regardless of baseline AD severity. | |
| Seed-1.6-2025-06-15 [51],49.91,,,,,49.91,54.61,38.30,49.32,48.75,46.06,77.17,34.58,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,None | |
| GPT-5-mini-2025-08-07 [45],48.67,,,,,48.67,52.47,34.10,55.52,56.69,52.51,77.77,44.66,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,None | |
| Grok-4-2025-07-09 [62],47.92,,,,,47.92,47.01,37.80,46.84,63.56,26.90,79.27,19.40 †,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,"† indicates cases where generations were truncated due to overlong chains of thought, yielding no final answer; such instances are counted as incorrect, which depresses the score." | |
| InternVL3-78B [79],47.55,,,,,47.55,52.72,30.50,50.95,49.52,42.00,71.16,31.10,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,None | |
| GPT-5-nano-2025-08-07 [45],43.22,,,,,43.22,35.81,28.90,47.81,41.48,46.05,67.92,35.59,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,None | |
| InternVL3-8B [79],42.14,,,,,42.14,41.15,28.00,46.25,41.54,41.36,60.92,30.00,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,None | |
| Qwen2.5-VL-72B-Instruct [1],35.77,,,,,35.77,47.41,32.50,47.81,42.40,38.37,69.22,32.54,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,None | |
| Random Choice,34.0,,,,,34.00,0.0,25.00,24.98,32.35,34.80,33.93,25.08,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,VSI random choice here is chance level(Frequency). | |
| Qwen2.5-VL-7B-Instruct [1],32.3,,,,,32.30,37.64,26.80,39.07,36.05,35.03,62.16,26.78,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,None | |
| Easi-CRISPR,30.0,,,,,,,,,,,,,,,,30–60%,,,Easi-CRISPR for creating knock-in and conditional knockout mouse models using long ssDNA donors,https://doi.org/10.1038/nprot.2017.153,"Typically 30-60% efficiency, reaching as high as 100% in some cases." | |
| Qwen2.5-VL-3B-Instruct [1],27.0,,,,,27.00,33.14,28.60,42.47,37.60,37.83,60.19,21.86,,,,,,,EASI,https://arxiv.org/pdf/2508.13142.pdf,None | |
| EASI,0.47,,,,,,,,,,,,,,,,,0.75,,Development and Validation of a Tool to Improve Physician Identification of Elder Abuse: The Elder Abuse Suspicion Index (EASI)©,https://doi.org/10.1080/08946560801973168,The EASI had an estimated sensitivity and specificity of 0.47 and 0.75 | |
| placebo,-1.3,,,,,,,,,,,,,,,,,,-1.3,"Phase 2a, randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study of a H<sub>4</sub>R‐antagonist (<scp>JNJ</scp>‐39758979) in<scp>J</scp>apanese adults with moderate atopic dermatitis",https://doi.org/10.1111/1346-8138.12726,at week 6 | |
| JNJ-39758979 300 mg,-3.0,,,,,,,,,,,,,,,,,,-3.0,"Phase 2a, randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study of a H<sub>4</sub>R‐antagonist (<scp>JNJ</scp>‐39758979) in<scp>J</scp>apanese adults with moderate atopic dermatitis",https://doi.org/10.1111/1346-8138.12726,at week 6 | |
| JNJ-39758979 100 mg,-3.7,,,,,,,,,,,,,,,,,,-3.7,"Phase 2a, randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study of a H<sub>4</sub>R‐antagonist (<scp>JNJ</scp>‐39758979) in<scp>J</scp>apanese adults with moderate atopic dermatitis",https://doi.org/10.1111/1346-8138.12726,at week 6 | |